Phase 1/2 Study of HS-10375 in Patients with Advanced or Metastatic Non-Small-Cell Lung Cancer(NSCLC)

Summary

HS-10375 is an oral, highly selective, small molecular inhibitor of EGFR C797S. This study will evaluate the safety, tolerability, pharmacokinetics and clinical activity of HS-10375 in Chinese advanced or metastatic NSCLC.

Timeline

Start

2022-03-02

Primary completion

2025-03-31

Completion

2026-03-31

Publications

• Zhan J, Xue J, Wu L, Zhang Z, Wang Q, Ma Y, Huang Y, Yang Y, Zhao Y, Fang W, Zhang Y, Liu Q, Xu W, Yang Y, Chen Z, Song B, Sun D, Sun X, Gao P, Zhao H, Zhang L. HS-10375, a selective EGFR C797S tyrosine kinase inhibitor, in advanced non-small cell lung cancer. J Transl Med. 2025 Jun 4;23(1):628. doi: 10.1186/s12967-025-06613-0.

Drugs

Indications